Domestic vaccines “go global”



While consolidating its position in the domestic market and continuously optimizing its sales network, the company is steadily expanding its international operations, driving its products into global markets.

Currently, our overseas business expansion spans multiple regions, including Southeast Asia, South Asia, the Middle East, Africa, and Latin America, with a product portfolio that encompasses 13-valent and 23-valent pneumococcal vaccines, varicella vaccine, combination vaccines, and other varieties.

29 +

Products under application for overseas registration

15 +

Countries for which overseas registration is being applied for

15 +

Countries with Overseas Cooperation Agreements

5 +

International Cooperation Project

Minhai Biotechnology

International Registration Certificate



QP certification, vaccine registration certificate, GMP certificate

GMP Certification for the Beijing Minhai Production Facility in Côte d’Ivoire

GMP Certification for the Beijing Minhai Production Facility in Côte d’Ivoire

Registration Certificate for Measles Vaccine Concentrate, Pakistan

Registration Certificate for Measles Vaccine Concentrate, Pakistan

Uzbekistan Registration Certificate for Quadrivalent Vaccine

Uzbekistan Registration Certificate for Quadrivalent Vaccine

Registration Certificate for the Original Solution of the Bangladesh BCG–Mycobacterium leprae Bivalent Vaccine

Registration Certificate for the Original Solution of the Bangladesh BCG–Mycobacterium leprae Bivalent Vaccine

Collaboration Model



Finished goods distribution

Export of finished vaccine products

Register and list for sale in the target country.

Raw liquid export

Export of raw materials/semi-finished products

Repackaged by local partners

Technology transfer

Overseas partners engage in technology transfer,

Local repackaging, etc.